An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells

The role of microenvironment and immunity in drug response in leukemia

(2016) Emyr Bakker et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

CD19 chimeric antigen receptor T cell therapy for haematological malignancies

(2015) Sara Ghorashian et al.   BRITISH JOURNAL OF HAEMATOLOGY

CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia

(2015) C. L. Lorentzen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

(2015) Hanren Dai et al.   OncoImmunology

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

(2014) Yao Wang et al.   CLINICAL IMMUNOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Biomarkers in T-cell therapy clinical trials

(2013) Simon F. Lacey et al.   CYTOTHERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies

(2013) Jan A. Burger et al.   SEMINARS IN CANCER BIOLOGY

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL

(2011) P. Christopoulos et al.   BLOOD

The clinical management of tumour lysis syndrome in haematological malignancies

(2011) Andrew Will et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies

(2011) L. A. Marr et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

(2011) L. H. Butterfield et al.   CLINICAL CANCER RESEARCH

Biomarkers in T cell therapy clinical trials

(2011) Michael Kalos   Journal of Translational Medicine

Defining the critical hurdles in cancer immunotherapy

(2011) Bernard A Fox et al.   Journal of Translational Medicine

The Tumor Lysis Syndrome

(2011) Scott C. Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Gene modulation and immunoregulatory roles of Interferonγ

(2009) Banishree Saha et al.   CYTOKINE